DiaMedica Therapeutics (DMAC) Gains from Investment Securities: 2017-2024
Historic Gains from Investment Securities for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to $30,000.
- DiaMedica Therapeutics' Gains from Investment Securities rose 9.23% to $71,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $75,000, marking a year-over-year change of. This contributed to the annual value of $30,000 for FY2024, which is 400.00% up from last year.
- As of FY2024, DiaMedica Therapeutics' Gains from Investment Securities stood at $30,000, which was up 400.00% from $6,000 recorded in FY2023.
- DiaMedica Therapeutics' Gains from Investment Securities' 5-year high stood at $446,000 during FY2022, with a 5-year trough of $6,000 in FY2023.
- In the last 3 years, DiaMedica Therapeutics' Gains from Investment Securities had a median value of $30,000 in 2024 and averaged $160,667.
- Per our database at Business Quant, DiaMedica Therapeutics' Gains from Investment Securities plummeted by 98.65% in 2023 and then skyrocketed by 400.00% in 2024.
- DiaMedica Therapeutics' Gains from Investment Securities (Yearly) stood at $41,000 in 2020, then spiked by 221.95% to $132,000 in 2021, then skyrocketed by 237.88% to $446,000 in 2022, then crashed by 98.65% to $6,000 in 2023, then spiked by 400.00% to $30,000 in 2024.